Development and validation of a clinical risk score predicting the no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction

Cardiology (Switzerland)

Volumn 124, Issue 3, 2013, Pages 153-160

  Wang, Jin Wen ^a   Chen, Yun Dai ^a   Wang, Chang Hua ^b   Yang, Xin Chun ^c   Zhu, Xiao Ling ^b   Zhou, Zi Qiang ^d  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Acute myocardial infarction; No reflow; Percutaneous coronary intervention; Risk score; ST segment elevation myocardial infarction

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL ASSESSMENT TOOL; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; VALIDATION STUDY;

EID: 84874809860     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000346386     Document Type: Article

References (27)

1. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
2. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E: Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002; 105: 1909-1913.
3. Rezkalla SH, Kloner RA: Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2008; 72: 950-957.
4. Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, Carrozza JP Jr, Kuntz RE, Baim DS: Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994; 89: 2514-2518.
5. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, Higashino Y, Fujii K, Minamino T: Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996; 93: 223-228.
6. Brosh D, Assali AR, Mager A, Porter A, Hasdai D, Teplitsky I, Rechavia E, Fuchs S, Battler A, Kornowski R: Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol 2007; 99: 442-445.
7. Bolognese L, Carrabba N, Parodi G, Santoro GM, Buonamici P, Cerisano G, Antoniucci D: Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 2004; 109: 1121-1126.
8. Cura FA, L'Allier PL, Kapadia SR, Houghtaling PL, Dipaola LM, Ellis SG, Topol EJ, Brener SJ, GUSTO IIb, RAPPORT Investigators: Predictors and prognosis of suboptimal coronary blood flow after primary coronary angioplasty in patients with acute myocardial infarction. Am J Cardiol 2001; 88: 124-128.
9. Niccoli G, Kharbanda RK, Crea F, Banning AP: No-reflow: again prevention is better than treatment. Eur Heart 2010; 31: 2449-2455.
10. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB Sr, Newton-Cheh C, Yamamoto JF, Magnani JW, Tadros TM, Kannel WB, Wang TJ, Ellinor PT, Wolf PA, Vasan RS, Benjamin EJ: Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009; 373: 739-745.
11. Gray A, Goodacre S, Nicholl J, Masson M, Sampson F, Elliott M, Crane S, Newby DE, 3CPO Trialists: The development of a simple risk score to predict early outcome in severe acute acidotic cardiogenic pulmonary edema: the 3CPO score. Circ Heart Fail 2010; 3: 111-117.
12. Ganz W: The thrombolysis in myocardial infarction (TIMI) trial. N Engl J Med 1985; 313: 1018.
13. van't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F: Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 1998; 97: 2302-2306.
14. Niccoli G, Burzotta F, Galiuto L, Crea F: Myocardial no-reflow in humans. J Am Coll Cardiol 2009; 54: 281-292.
15. Takahashi T, Hiasa Y, Ohara Y, Miyazaki S, Ogura R, Miyajima H, Yuba K, Suzuki N, Hosokawa S, Kishi K, Ohtani R: Relation between neutrophil counts on admission, microvascular injury, and left ventricular functional recovery in patients with an anterior wall first acute myocardial infarction treated with primary coronary angioplasty. Am J Cardiol 2007; 100: 35-40.
16. Turschner O, D'Hooge J, Dommke C, Claus P, Verbeken E, De Scheerder I, Bijnens B, Sutherland GR: The sequential changes in myocardial thickness and thickening which occur during acute transmural infarction, infarct reperfusion and the resultant expression of reperfusion injury. Eur Heart J 2004; 25: 794-803.
17. Galiuto L, DeMaria AN, del Balzo U, May-Newman K, Flaim SF, Wolf PL, Kirchengast M, Iliceto S: Ischemia-reperfusion injury at the microvascular level: treatment by endothelin A-selective antagonist and evaluation by myocardial contrast echocardiography. Circulation 2000; 102: 3111-3116.
18. Duilio C, Ambrosio G, Kuppusamy P, DiPaula A, Becker LC, Zweier JL: Neutrophils are primary source of O2 radicals during reperfusion after prolonged myocardial ischemia. Am J Physiol Heart Circ Physiol 2001; 280:H2649-H2657.
19. Niccoli G, Lanza GA, Spaziani C, Altamura L, Romagnoli E, Leone AM, Fusco B, Trani C, Burzotta F, Mazzari M.A, Mongiardo R, Biasucci LM, Rebuzzi AG, Crea F: Baseline systemic inflammatory status and no-reflow phenomenon after percutaneous coronary angioplasty for acute myocardial infarction. Int J Cardiol 2007; 117: 306-311.
20. Hoffmann R, Suliman H, Haager P, Christott P, Lepper W, Radke PW, Ortlepp J, Blindt R, Hanrath P, Weber C: Association of C-reactive protein and myocardial perfusion in patients with ST-elevation acute myocardial infarction. Atherosclerosis 2006; 186: 177-183.
21. Singh M, Mathew V, Garratt KN, Berger PB, Grill DE, Bell MR, Rihal CS, Holmes DR Jr: Effect of age on the outcome of angioplasty for acute myocardial infarction among patients treated at the Mayo Clinic. Am J Med 2000; 108: 187-192.
22. Barakat K, Wilkinson P, Deaner A, Fluck D, Ranjadayalan K, Timmis A: How should age affect management of acute myocardial infarction? A prospective cohort study. Lancet 1999; 353: 955-959.
23. Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K, Kuroda T, Tanaka K, Masuyama T, Hori M, Fujii K: Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003; 41: 1-7.
24. Rott D, Behar S, Gottlieb S, Boyko V, Hod H: Usefulness of the Killip classification for early risk stratification of patients with acute myocardial infarction in the 1990s compared with those treated in the 1980s. Israeli Thrombolytic Survey Group and the Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) Study Group. Am J Cardiol 1997; 80: 859-864.
25. Funovic P, Korda M, Kubant R, Barlag RE, Jacob RF, Mason RP, Malinski T: Effect of betablockers on endothelial function during biological aging: a nanotechnological approach. J Cardiovasc Pharmacol 2008; 51: 208-215.
26. Vrints CJ: Pathophysiology of the no-reflow phenomenon. Acute Card Care 2009; 11: 69-76.
27. Nallamothu BK, Bradley EH, Krumholz HM: Time to treatment in primary percutaneous coronary intervention. N Engl J Med 2007; 357: 1631-1638.